DRIO (DarioHealth) Stock Based Compensation: $8.46 Mil (TTM As of Mar. 2026)


DRIO DarioHealth Corp DRIO
57 GF Score
Price $7.22
GF Value $7.04
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is DarioHealth Stock Based Compensation?

DarioHealth DRIO +4.94% 57 Stock Based Compensation is $8.46 Mil as of Mar. 2026. GuruFocus rates DRIO with a GF Score™ of 57/100 and a GF Value™ of $7.04 (Fairly Valued). The stock has 4 warning signs investors should review.

DarioHealth's Stock Based Compensation for the three months ended in Mar. 2026 was $1.44 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $8.46 Mil.

DarioHealth Stock Based Compensation Related Terms

DarioHealth Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for DarioHealth's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DarioHealth Stock Based Compensation Chart

DarioHealth Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.97 16.98 19.70 15.80 9.37

DarioHealth Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.34 2.04 2.95 2.04 1.44
DRIO
57GF Score
DarioHealth Corp DRIO
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DarioHealth Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.46 Mil.

What does a Stock Based Compensation of $8.46 Mil mean?
DarioHealth (DRIO) has a Stock Based Compensation of $8.46 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for DarioHealth and its competitors.
Is DarioHealth's Stock Based Compensation too high?
DarioHealth's current Stock Based Compensation is $8.46 Mil. Overall, DarioHealth has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DarioHealth's Stock Based Compensation compare to BEAT and ONMD?
DarioHealth's Stock Based Compensation of $8.46 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Healthcare Providers & Services company?
A good Stock Based Compensation depends on the Healthcare Providers & Services industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for DarioHealth and its competitors. DarioHealth's current Stock Based Compensation is $8.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DarioHealth stock overvalued right now?
Based on GuruFocus' analysis, DarioHealth (DRIO) is currently considered Fairly Valued. The stock's GF Value™ is $7.04, compared to a current price of $7.22 — trading 2.6% above its estimated fair value. The current Stock Based Compensation is $8.46 Mil. DarioHealth's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For DarioHealth (DRIO), the current Stock Based Compensation is $8.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DarioHealth (DRIO) Overvalued in 2026?

Based on GuruFocus' analysis, DarioHealth stock appears to be overvalued. The current stock price of $7.22 is trading 2.6% above its estimated GF Value™ of $7.04. GuruFocus considers DarioHealth to be Fairly Valued.

Key valuation signals for DRIO:

  • Stock Based Compensation: $8.46 Mil
  • GF Value™: $7.04 vs. price of $7.22 (2.6% above fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the DRIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DarioHealth Business Description

Address 322 West 57th Street, New York, NY, USA, 10019
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
57GF Score

Get the complete analysis for DRIO

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.22
Price
$7.04
GF Value